Biotech Movers

Quarter 1 2018

ALDR +17.37% ( Eptimezumab met primary endpoint in PROMISE 2 trial
APOP +37.78% (Successful transplant using ApoGraft
BOLD +14.86% (-23.32% after 2 days) (*positive data of 1st dose cohort of ASPIRO Ph1/2 of AT132, record high)
CCXI +39.42% (secures up to $100M in new capital commmitments
GBT +19.07% ( FDA Breakthrough Therapy Designation for Voxelotor.)
NVAX +59.40% (Price target raised to $10 FROM $2.25 at B. Riley FBR
NVRO +14.40% ( receives FDA approval for SENZA ll SCS System)
PTIE +103.15% (Positive Topline for Nasal Abuse
ARDM (-33.92%) FDA Antimicrobial Drugs Advisory Committee did not rec'd approval
AXON -56.98% ( intepirdine did not meet primary endpoint
AXSM -35% ( discontinued CREATE-1 trial)
EIGR (-49.38%) failed 2 LIBERTY to meet primary endpoint
EXAS -9.95% (sell off on ASCO abstract)
INSY -26.31% (+11.23% weekly gain Jan 2-5* despite 1 dy sell off*)
KALA -29.28% Topline result for two phase 3 trials
OHRP -81.33% data did not meet endpoint
Sell the Gap
BOLD -23.30% in 2 days ( giving up all its gain after AT132 P1/2 data release)
Reversal off Lows
KALA +32% bounce in 5 days since initial gap down reaction on P3 result of Topline data

Quarter 4 2017

ADMS +21.01% (*Evercore ISI gives it $85 price target, plus Point72 reported 5.1% passive stake*)
ANAB +101% (reported positive results of P2a ANB020)
ARDX +44.44% (*Tepanor study meets endpoints*)
ARGX +78.8% (+91% weekly gain; ASH'17 data update pn Phase 1/2 clinical trials for AML & CTCL ARGX-110)
BIOC +69.12% (* announces issuance of U.S patent core to BIOC Target Select Assays for ctDNA)
BLUE +17.91% (*ASH '17 data presentation of its Lentiglobin; record high $10bil MC)
CBIO +29.62% (announces acceleration of Phase 1/2 trial of CB 2679d/lSU304 in individuals w/ Hemophilia B)
CLSN +123.33% (*weekly gain, rallies on aanouncement of final clinical & translational research data from its OVATION Study*)
ECYT +307.8% (*weekly gain on completion of an exclusive worldwide license of PSMA-617 from ABZ GmbH*)
FLXN +23.78% (*weekly gain, FDA approved its Zilretta drug*)
INFI +123.35% (Wells Fargo Upgrade to $5PT,cites IPI-549 potential*)
MDGL +88.29% (met primary endpoint in a P2 NASH study for MGL-3196*)
MNKD +131.80% (*weekly gain, on FDA update on Affreza prescribing information*)
MRNS +39.58% (*sympathy move with MDGL*)
ONCS +60.00% updated data from P2 OMS I-102 .
OTIC +83.04% reporting 'positive' Phase 3 Otividex trial
PTI +161.28% (*positive data from PTI-428,PTI-801,& PTI-808*)
RVNC +33.65% (RT002 met primary and secondary endpoints)
SAGE +54.25% (positive trial results in postpartum depression)
VKTX +35.10% weekly gain (* sell the gap initial reaction, next 2 days +45% bounce, rally in sympathy move w/ MDGL*)
VTVT +44.82% weekly gain (rallies on increase stake of Ron Perelman)
ACOR -39.72% (tozadenant for Parkinson's groups, five of which were fatal)
ACRX -59.81% (*receives CRL from FDA for DSUVIA*)
CALA -41% in two days. (CB-839 combo fail to impress investors at SITC)
FPRX -40.90% (*tanked on Cabiralizumab abstract presented on SITC*)
GALT -30.65% (P2b NASH-CX trial update)
GBT -14.24% (ASH '17 presented treatment for SCD #Voxelotor drug.
JUNO -14.33% ~ initial reaction, -23.82% for the week* (ASH '17 reported additional data from TRANSCEND study)
JUNO -14.34% (*ASH '17 presented addtl data from TRANSCEND study of JCAR017*)
ONCE -34.97% (*ASH '17 presented SPK-8011; -50% intraday low; 52weeks low print*)
RARX -37.32% (* Met Primary Endpoint for Phase 2 RA101495, sold off on efficacy inferior to ALXN1210*
RDHL -29.60% offering of 4,090,909 American Depositary Shares, public offering price of $5.50 per ADS for gross proceeds to $22.5m
SYRS -31.69% (*ASH '17 presented new preclinical data on SY-1365; intraday low -49%)
Sell the Gap
AIMT +28.37% from +56% or 39.90 premarket high*; DVBT PH3 failure in peanut allergy is AIMT gain*
VKTX +9.12% (*+39% intraday, +52% premarket, sympathymove with MDGL on positive P2 data of MGL-3196*; after 2 days total rally +45%*)
VSTM -16.86% (+57% premarket; +10.6% intraday; ASH '17 released PH3 result of DUO*)
Reversal off Lows
BHVN -4.86% (*-28.70% intraday low, TRIGRILUZOLE Phase2/3 no difference from Placebo
GALT unchanged* weekly performance (*initial reaction is -32% 2 days rally brought it back to unchanged for the week*)
NKTR +5.71% (-5% premarket low, INHALE Ph3 study did not meet endpoint)

Quarter 3 2017

AKTX +51.20% (*Plans to advance COVERSIN towards PH3)
ALNY +49.32% (meets all endpoint for APOLLO Phase3 of PATISIRAN*)
CLSN +123.33% (*weekly gain, rallies on aanouncement of final clinical & translational research data from its OVATION Study*)
ZGNX +172.23% (*Meets endpoint ZX008 of Phase 3 trial for Dravet syndome*)
ZYNE +34.19% *ZYN002 gel meets primary endpoint in Phase 2 Fragile X syndrome trial.*
AXON -72.47% (*Failed Phase 3 MINDSET study*)
GNCA -72.40% (*Ceased GEN 003 and shifted focus towards Immunocology*)
ICPT -35.09% (FDA safety announcement on OCALIVA*)
VSAR -85.42% (*Phase 3 of SOMAVARATAN did not meet primary endpoint*)
Sell the Gap
NBRV +29.30% from +105% intraday high* (rallies on LEAP 1 trial)
Reversal off Lows
PTCT +8.05% (*-23% intraday low to positive territory*)

Please select phase first
Disclaimer! This is NOT an investment advice. The data result herein is purely speculation only. You must do your own due diligence and mitigate your risk. You acknowledge that will not be held responsible and accountable for any losses you may incur using our Biotech Data Calculator. Please consult your own financial adviser before executing trades.